Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis

Next Previous
X
Search
Trial Profile

Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olvimulogene nanivacirepvec (Primary)
  • Indications Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Genelux Corporation

    • Most Recent Events

    • 17 May 2018 Results of the phase I, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 09 Mar 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 12 Mar 2014 Planned End Date changed from 1 Nov 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top